Enveric Biosciences (ENVB) Short term Debt (2010 - 2021)
Enveric Biosciences (ENVB) posted Short term Debt of $148604.0 for Q2 2021, down 91.41% sequentially from $1.7 million in Q3 2020, and down 93.64% YoY from $2.3 million in Q2 2020.
Enveric Biosciences (ENVB) Short term Debt (2010 - 2021) Analysis & Trends
Enveric Biosciences has reported Short term Debt for 9 years, with the latest figure at $148604.0 in Q2 2021.
- Quarterly Short term Debt fell 93.64% year-over-year to $148604.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $148604.0 (down 93.64% YoY) and the FY2019 annual result came in at $22409.0, up 247.43% from the prior year.
- Short term Debt eased to $148604.0 in Q2 2021 per ENVB's latest filing, from $1.7 million in the prior quarter.
- Over five years, Short term Debt peaked at $4.6 million in Q1 2020 and troughed at $6450.0 in Q4 2018.
- A 5-year average of $2.3 million and a median of $2.3 million in 2018 frame the typical range for Short term Debt.
- The widest YoY moves for Short term Debt: up 786.64% in 2018, down 99.84% in 2018.
- Over 5 years, Short term Debt stood at $4.1 million in 2017, then slumped by 99.84% to $6450.0 in 2018, then soared by 247.43% to $22409.0 in 2019, then jumped by 7618.33% to $1.7 million in 2020, then tumbled by 91.41% to $148604.0 in 2021.
- According to Business Quant data, Short term Debt over the past three periods registered $148604.0, $1.7 million, and $2.3 million for Q2 2021, Q3 2020, and Q2 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 148,604.00 |
| Sep 30, 2020 | 1.73 Mn |
| Jun 30, 2020 | 2.34 Mn |
| Mar 31, 2020 | 4.55 Mn |
| Dec 31, 2019 | 22,409.00 |
| Sep 30, 2019 | 3.43 Mn |
| Mar 31, 2019 | 4.19 Mn |
| Dec 31, 2018 | 6,450.00 |
| Sep 30, 2018 | 3.60 Mn |
| Jun 30, 2018 | 2.34 Mn |
| Mar 31, 2018 | 3.26 Mn |
| Dec 31, 2017 | 4.05 Mn |
| Sep 30, 2017 | 406,156.00 |
| Jun 30, 2017 | 406,031.00 |
| Mar 31, 2017 | 3.96 Mn |
| Dec 31, 2016 | 3.09 Mn |
| Dec 31, 2015 | 1.24 Mn |
| Sep 30, 2012 | 5,000.00 |
| Dec 31, 2010 | 40,000.00 |